"epidermal growth" trang 14 - tải miễn phí từ tailieunhanh
A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
9    1    1
Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy

Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy
9    5    1
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: A real-world study

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: A real-world study
11    4    1
Intracranial efficacy and safety of furmonertinib 160mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy

Intracranial efficacy and safety of furmonertinib 160mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy
11    5    1
Prognostic value of CYFRA 21−1 and Ki67 in advanced NSCLC patients with wild-type EGFR

Prognostic value of CYFRA 21−1 and Ki67 in advanced NSCLC patients with wild-type EGFR
10    3    1
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFRmutated, non–small cell lung cancer

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFRmutated, non–small cell lung cancer
8    6    1
Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements

Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements
12    6    1
Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide

Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide
14    7    1
Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells

Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells
8    7    1
Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: An ambispective cohort study

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: An ambispective cohort study
10    6    1
Association between NDRG1 protein expression and aggressive features of breast cancer: A systematic review and meta-analysis

Association between NDRG1 protein expression and aggressive features of breast cancer: A systematic review and meta-analysis
11    8    1
PIK3CA mutations associated with a poor postoperative prognosis in patients with pulmonary pleomorphic carcinoma: A retrospective cohort study

PIK3CA mutations associated with a poor postoperative prognosis in patients with pulmonary pleomorphic carcinoma: A retrospective cohort study
10    7    1
Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: A possible association with Lyme disease?

Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: A possible association with Lyme disease?
11    7    1
Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer

Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer
6    8    1
Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel

Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel
10    10    1
Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: A prospective observational study

Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: A prospective observational study
10    5    1
Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation
12    5    1
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)
6    8    1
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: A phase I clinical trial

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: A phase I clinical trial
9    1    1
Development and validation of MRI-based radiomics signatures as new markers for preoperative assessment of EGFR mutation and subtypes from bone metastases

Development and validation of MRI-based radiomics signatures as new markers for preoperative assessment of EGFR mutation and subtypes from bone metastases
9    1    1